Pfizer 專利celecoxib延長(適應症) 成功痛擊學名藥廠 !!

輝瑞鎮痛藥專利獲延長 起多家訴仿製藥公司 鉅亨網新聞中心(來源：北美新浪)2013-03-06 08:31:49新浪財經訊 北京時間3月6日凌晨消息，世界最大製藥商輝瑞公司(PFE)周二宣佈，其銷售額達數十億美元的鎮痛藥西樂葆( Celebrex )已獲美藥品監管機構授予再版專利，從而將其在這款藥物上的獨家營銷權延長一年半，至2015年12月2日。西樂葆去年在美國的銷售額高達17億美元以上，該藥原始的基本專利將於2014年5月30日到期。據統計，品牌藥一旦失去專利保護，在低成本仿製藥的競爭下，銷售額往往會很快下降80%以上。 輝瑞表示，已對幾家仿製藥製造商提起訴訟，后者正在尋求美國食品和藥品管理局(FDA)的批准，希望能從2014年開始在美國出售西樂葆的仿製版本。被起訴的包括以色列梯瓦製藥(TEVA)、米蘭製藥(MYL)、 Actavis Inc(原華生製藥，股票代碼ACT)、印度魯賓製藥(Lupin Pharmaceuticals)，以及Apotex。輝瑞希望能夠阻止這些公司在新的專利到期日之前出售仿製版的西樂葆。(羽箭)

 (Reuters) Mar 5, 2013 11:13am EST - U.S. regulators granted Pfizer Inc a reissued patent on its multibillion-dollar Celebrex pain drug that extends its marketing exclusivity until early December 2015, the company said on Tuesday. That will give Pfizer an additional 1 1/2 years of selling a drug that had U.S. sales of more than $1.7 billion in 2012, before cheaper generic versions begin to hit the market at the end of 2015. Branded drugs can quickly lose upwards of 80 percent of sales once multiple generic versions become widely available. The original basic patent for Celebrex - known chemically as celecoxib - expires on May 30, 2014, including six months of pediatric exclusivity for testing the drug in children. But the U.S. Patent & Trademark Office agreed to the reissued patent covering methods of treating arthritis and other approved conditions, Pfizer said. Pfizer said it filed lawsuits against several generic drugmakers that are seeking permission from the U.S. Food and Drug Administration to sell a generic version of the drug in the United States beginning in May 2014. Pfizer said it sued Teva Pharmaceutical Industries Ltd; Mylan Inc; Watson Pharmaceuticals, which has since changed its name to Actavis Inc; Lupin Pharmaceuticals; and Apotex to try to prevent them from selling their generic Celebrex until the new patent expires on December 2, 2015. Shares of Pfizer were up 1.4 percent at $28.09 in morning trading on the New York Stock Exchange.

 

FDA 過了Kadcyla (trastuzumab emtansine) !! 開發藥物難以承受之重~

FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer MONDAY, 25 FEBRUARY 2013  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. Kadcyla is the fourth medicine from Roche to receive FDA approval for people with advanced cancers within the past two years. An antibody-drug conjugate (ADC) is a new kind of targeted cancer medicine that can attach to certain types of cancer cells and deliver chemotherapy directly to them. Kadcyla is the first FDA-approved ADC for treating HER2-positive mBC, an aggressive form of the disease. "Kadcyla is an antibody-drug conjugate representing a completely new way to treat HER2-positive metastatic breast cancer, and it helped people in the EMILIA study live nearly six months longer," said Hal Barron, M.D., Roche's Chief Medical Officer and Head, Global Product Development. "We currently have more than 25 antibody-drug conjugates in our pipeline and hope this promising approach will help us deliver more medicines to fight other cancers in the future." Kadcyla is made up of the antibody, trastuzumab, and the chemotherapy, DM1, joined together using a stable linker. Kadcyla combines the mechanisms of action of both trastuzumab and DM1, and it is the first Roche ADC approved by the FDA. Roche has studied ADC science for more than a decade and has eight ADCs in Phase I or Phase II studies for different types of cancer. Roche has also submitted a Marketing Authorisation Application to other Regulatory Authorities around the world, including the European Medicines Agency (EMA), for Kadcyla for the treatment of people with HER2-positive mBC. This application is currently under review by the EMA.

Kadcyla efficacy in HER2-positive mBC The FDA approval of Kadcyla is based on results from EMILIA (TDM4370g/BO21977), an international, Phase III, randomised, open-label study comparing Kadcyla alone to lapatinib in combination with Xeloda (capecitabine) in 991 people with HER2-positive locally advanced breast cancer or mBC who had previously been treated with Herceptin and a taxane chemotherapy. Results include:(1) The study met both co-primary efficacy endpoints of overall survival and progression-free survival (PFS; as assessed by an independent review committee). People who received Kadcyla lived a median of 5.8 months longer (overall survival) than those who received the combination of lapatinib and Xeloda, the standard of care in this setting (median overall survival: 30.9 months vs. 25.1 months). People receiving Kadcyla experienced a 32 percent reduction in the risk of dying compared to people who received lapatinib and Xeloda (HR=0.68; p=0.0006). People who received Kadcyla lived significantly longer without their disease getting worse (PFS) compared to those who received lapatinib plus Xeloda (HR=0.65, 35 percent reduction in the risk of disease worsening or death, p<0.0001; median PFS 9.6 months vs. 6.4 months). No new safety signals were observed and adverse events (AEs) were consistent with those seen in previous studies, with fewer people who received Kadcyla experiencing Grade 3 or higher (severe) AEs than those who received lapatinib plus Xeloda (43.1 percent vs. 59.2 percent). For people receiving Kadcyla, the most common (occurring in more than 2 percent of participants) Grade 3 or higher AEs were low platelet count (14.5 percent), increased levels of enzymes released by the liver and other organs (8.0 percent), low red blood cell count (4.1 percent), low levels of potassium in the blood (2.7percent), nerve problems (2.2percent) and tiredness (2.5percent).

About Kadcyla Kadcyla is an ADC being studied in HER2-positive cancers. It is the first ADC to result from Roche and Genentech's 30 years of HER2 pathway research and the third medicine Roche has developed for the treatment of HER2-positive breast cancer. Like Herceptin, Kadcyla binds to HER2-positive cells and is thought to block out-of-control signals that make the cancer grow while also calling on the body's immune system to attack the cancer cells. Once Kadcyla is taken up by those cells, it is designed to destroy them by releasing the DM1 inside the cells. Roche licenses technology for Kadcyla under an agreement with ImmunoGen, Inc.

【FDA】晚期乳腺癌新药T-DM1获批 发布时间：2013-2-25 来源：药品资讯网信息中心 美国食品和药物管理局（FDA）2月22日批准Kadcyla(ado-trastuzumab emtansine)用于治疗HER-2阳性晚期转移性乳腺癌。 HER2是一种在细胞表面正常生长的相关蛋白。它在某些类型的癌细胞（HER2阳性）数量增加，其中包括一些乳腺肿瘤。在这些HER2阳性乳腺癌中，HER2蛋白数量增加有助于癌细胞的生长和存活。Kadcyla目标是用于治疗已经接受过曲妥珠单抗和一线紫杉烷类化疗无效的乳腺癌患者。"Kadcyla是将曲妥珠单抗与一种干扰肿瘤细胞的生长的药物DM1相结合" FDA的药品评价和研究中心的血液学和肿瘤学产品办公室主任Richard Pazdur博士介绍说，"Kadcyla将药物输送至肿瘤灶使肿瘤缩小，延缓疾病进展，延长生存期。这是第四个批准的针对于HER2蛋白的药物。"在临床研究过程中Kadcyla被简称为T-DM1，其接受了FDA的优先审查程序。当没有有效的替代治疗存在或与已批准药物相比能够提供显著的生存改善时，FDA将提供快速的六个月的药物审查程序，由此为患者提供安全有效的治疗。其他FDA批准的用于治疗HER2阳性乳腺癌的药物分别为：曲妥珠单抗（1998年），拉帕替尼（2007年）和帕妥珠单抗（2012年）。Kadcyla的安全性和有效性通过一项临床研究确认，共991例患者，随机分配到接受Kadcyla或拉帕替尼联合卡培他滨。患者接受治疗直至癌症进展或不良反应无法耐受。这项研究的目的是患者的无进展生存（患者没有发生肿瘤进展的时间长度）和总生存期（患者在死亡之前的生存时间长度。 结果表明：接受Kadcyla治疗的患者中位无进展生存期为9.6个月，拉帕替尼联合卡培他滨治疗的患者为6.4个月。在Kadcyla组的患者中位总生存期为30.9个月，而拉帕替尼联合卡培他滨组为25.1个月。具体内容：NEJM：研究证明T-DM1治疗乳腺癌具备安全性和有效性Kadcyla批准时有一项黑框警告，提醒患者与卫生保健专业人员：该药物可引起肝脏毒性，心脏毒性和死亡。该药物同时也可以导致危及生命的严重出生缺陷，在使用Kadcyla进行治疗之前要进行妊娠试验。使用Kadcyla治疗患者最常见的不良反应有恶心、乏力、肌肉或关节疼痛、血小板水平降低（血小板减少）、肝酶水平升高、头痛和便秘。 乳腺癌是妇女第二大癌症相关死亡原因。根据美国国家癌症研究所提供的数据，估计2013年美国将有232340名妇女被诊断患有乳腺癌，39620名患者将死于乳腺癌。近20%乳腺癌患者的HER2蛋白数量有扩增。 Kadcyla、曲妥珠单抗和帕妥珠单抗均由加利福尼亚州南圣弗朗西斯科的基因泰克上市销售，该公司是罗氏集团的下属公司。拉帕替尼由葛兰素史克上市销售。

 

 

用telomere 長度 預測感冒 ! (非老化)

CD8CD28-细胞端粒较短的人群更易感染上呼吸道病毒 发布时间：2013-3-5 来源：药品资讯网信息中心较短的白细胞端粒长度与老化相关性疾病及涉及免疫系统情况的死亡有关，其中包括传染病、癌症及心血管疾病。然而，人们不知道白细胞端粒长度是否与年轻健康人群中的急性病有关。在线发表于2013年2月20日的《美国医学会杂志》上的一篇文章显示，在接种某种感冒病毒的健康成年人群中，那些在某些细胞中有着较短端粒长度（这是染色体末端的一个结构）的人比那些有着较长端粒长度的人更可能出现试验诱发的上呼吸道感染。 来自匹茨堡市卡内基-梅隆大学的Sheldon Cohen博士及其同事开展了一项研究，旨在确定白细胞，尤其是CD8CD28-T细胞中较短的端粒是否与年轻及中年人中的上呼吸道感染抵抗力下降及临床疾病有关。在2008年至2011年期间，宾西法尼亚州匹茨堡市有152名18-52岁的健康居民接受了外周血液中单核细胞（PBMCs）和亚组T细胞（CD4，CD8CD28+ ，CD8CD28-）的端粒长度评估。这些实验的参与者随后被隔离在单个的房间中，他们被给予了含有普通感冒病毒（鼻病毒39）的滴鼻剂，并接受了为期5天的是否会被感染并出现临床病症的监测。试验主要终点为感染（病毒脱落或病毒特异性抗体滴度增加4倍）和临床疾病（证实为感染且出现疾病体征）。 结果显示，69%的参与者（n=105）出现了呼吸道感染；整个样本中有22%（n=33）的人出现了临床病症（普通感冒），端粒较短与感染风险增加相关，且这种关联独立于病毒特异性抗体、人口统计学因素、避孕药物使用、季节、以及体重指数。分析表明，只有CD8CD28-亚组的端粒长度与临床病症的风险有关，而较短的端粒长度与该风险的增加有关。在有着最短端粒的参与者中，26%的人出现了临床病症。在那些有着最长端粒的组群中，临床病症的发生率为13%。此外，在CD8CD28-端粒长度与感染之间的相关性会随着年龄的增加而增加。 文章的作者从这项初步研究中得出结论，对于18到55岁的健康人群，较短的CD8CD28-细胞端粒长度与实验性接触鼻病毒后出现上呼吸道感染及临床病症有关。由于这些数据是初步的，因此它们的临床涵义还是未知的。

Susceptibility to flu may be found in your chromosomes SCI/TECH | Brooke Kuei How often do you get a cold? Have you noticed that you get sick more or less often than your friends? Carnegie Mellon Robert E. Doherty Professor of Psychology Sheldon Cohen recently identified a biological marker — an indicator of a biological state — that corresponds with one's susceptibility to the common cold. Telomeres are cap-like protein complexes found at the ends of chromosomes whose function is to protect those chromosomes during replication. It has long been known that as you age and undergo more cell replication, your telomeres shorten, leading to the possibility of aging-related diseases. What is remarkable about Cohen's work is the discovery that telomere length not only predicts susceptibility of disease in the elderly, but also does so for younger people. Cohen cites two reasons that led him to conduct a study on the correlation between telomere length in young adults and their ability to fight off disease: "First, even though telomere length decreases as we age, the evidence suggested that there was variation in telomere length even in young adults. Second, telomere length is often measured in white blood cells. Our interest is in how the immune system responds to infectious agents like cold viruses," he said. "The most prevalent diseases in the age group we study, 18-to-55-year-olds, are upper respiratory infections, and it seemed to us that those with shorter telomeres in key white blood cells would be less able to prevent cold viruses from replicating." Indeed, the results of Cohen's experiments aligned with his prediction. Cohen and his team measured the telomere length of white blood cells in 152 volunteers between the ages of 18 and 55. These volunteers were then quarantined for five days after being exposed to the virus that causes the common cold. "We have studied the role of psychological and behavioral factors in the common cold for over 30 years. Unlike most diseases, we can actually experimentally expose people to the disease-causing agent. Hence, colds have provided an excellent model for us," Cohen said. The results of the experiment showed that individuals with shorter telomere length were more likely to contract the common cold than those with longer telomeres. Another result of their experiment was the discovery that telomere length only started predicting an individual's susceptibility to the common cold for those who were about 22 or older. Telomere length was increasingly indicative of an individual's ability to fight off disease as the age of the individual increased. "The increased importance of telomere length with age is likely because the younger participants had fewer very short telomeres, or that their young immune systems were able to compensate for the loss of effective cells," Cohen said in a university press release. Sheldon and his team also found that a particular type of white blood cell — a CD8CD28- T-cytolytic cell — was the best indicator of the likelihood of contracting the cold because the telomeres found in CD8CD28- cells shorten at a more rapid speed than those found in other cell types. Now that it's known that telomere length corresponds with an individual's ability to fight off disease, the obvious question one might ask is, what factors — besides natural aging — affect telomere length? "Shorter telomere length is associated with traumaatic childhood experiences, with exposure to chronic enduring stressors, with poor health behaviors such as smoking and excessive consumption of alcohol, with lower levels of education, and with stable psychological dispositions like hostility," Cohen said. These factors may decrease telomere length through their effects on telomerase — an enzyme that rebuilds telomeres. Further studies with other viruses and natural infections will increase the understanding of how telomere length corresponds to susceptibility to disease. Perhaps, in the future, telomeres will be the key to improving human health. How often do you get a cold? Have you noticed that you get sick more or less often than your friends? Carnegie Mellon Robert E. Doherty Professor of Psychology Sheldon Cohen recently identified a biological marker — an indicator of a biological state — that corresponds with one's susceptibility to the common cold. Telomeres are cap-like protein complexes found at the ends of chromosomes whose function is to protect those chromosomes during replication. It has long been known that as you age and undergo more cell replication, your telomeres shorten, leading to the possibility of aging-related diseases. What is remarkable about Cohen's work is the discovery that telomere length not only predicts susceptibility of disease in the elderly, but also does so for younger people. Cohen cites two reasons that led him to conduct a study on the correlation between telomere length in young adults and their ability to fight off disease: "First, even though telomere length decreases as we age, the evidence suggested that there was variation in telomere length even in young adults. Second, telomere length is often measured in white blood cells. Our interest is in how the immune system responds to infectious agents like cold viruses," he said. "The most prevalent diseases in the age group we study, 18-to-55-year-olds, are upper respiratory infections, and it seemed to us that those with shorter telomeres in key white blood cells would be less able to prevent cold viruses from replicating." Indeed, the results of Cohen's experiments aligned with his prediction. Cohen and his team measured the telomere length of white blood cells in 152 volunteers between the ages of 18 and 55. These volunteers were then quarantined for five days after being exposed to the virus that causes the common cold. "We have studied the role of psychological and behavioral factors in the common cold for over 30 years. Unlike most diseases, we can actually experimentally expose people to the disease-causing agent. Hence, colds have provided an excellent model for us," Cohen said. The results of the experiment showed that individuals with shorter telomere length were more likely to contract the common cold than those with longer telomeres. Another result of their experiment was the discovery that telomere length only started predicting an individual's susceptibility to the common cold for those who were about 22 or older. Telomere length was increasingly indicative of an individual's ability to fight off disease as the age of the individual increased. "The increased importance of telomere length with age is likely because the younger participants had fewer very short telomeres, or that their young immune systems were able to compensate for the loss of effective cells," Cohen said in a university press release. Sheldon and his team also found that a particular type of white blood cell — a CD8CD28- T-cytolytic cell — was the best indicator of the likelihood of contracting the cold because the telomeres found in CD8CD28- cells shorten at a more rapid speed than those found in other cell types. Now that it's known that telomere length corresponds with an individual's ability to fight off disease, the obvious question one might ask is, what factors — besides natural aging — affect telomere length? "Shorter telomere length is associated with traumaatic childhood experiences, with exposure to chronic enduring stressors, with poor health behaviors such as smoking and excessive consumption of alcohol, with lower levels of education, and with stable psychological dispositions like hostility," Cohen said. These factors may decrease telomere length through their effects on telomerase — an enzyme that rebuilds telomeres. Further studies with other viruses and natural infections will increase the understanding of how telomere length corresponds to susceptibility to disease. Perhaps, in the future, telomeres will be the key to improving human health.

 

(The Lancet) 中國EV71疫苗phaseII 結果 !!!

手足口病EV71疫苗研究发布新成果 发布时间：2013-2-26 来源：药品资讯网信息中心近日，《柳叶刀》杂志在线发表题为《肠道病毒71型疫苗在中国健康幼儿和婴幼儿中的免疫原性和安全性：随机、双盲、安慰剂对照Ⅱ期临床试验》的研究论文，介绍中国新型手足口病EV71疫苗的Ⅱ期临床研究成果。美国CDC国家传染病中心肠道病毒中心主任Pallansch博士在同期《柳叶刀》杂志为该研究论文发表专业评论，充分肯定EV71疫苗Ⅱ期临床试验在疫苗的剂量、剂型和免疫程序上取得的成果，并对即将完成的该疫苗Ⅲ期临床试验寄予厚望。 此项研究由江苏省疾病预防控制中心、中国食品药品检定研究院、中国生物技术股份有限公司北京微谷生物医药有限公司等单位合作开展，探讨了疫苗人体免疫后的中和抗体转归，发现接种后第8个月抗体滴度出现显著降低，提出进行加强免疫的必要性；证明婴幼儿常规接种口服脊髓灰质炎疫苗未对接种EV71疫苗的免疫应答产生干扰；血清学研究结果支持开展Ⅲ期临床试验；提出适用于我国6个月~36个月龄婴幼儿和幼儿的适宜剂量和剂型为采用320U剂量佐剂疫苗2针免疫程序。 据悉，此项研究得到国家重大传染病和重大新药创新专项和支撑计划的支持。为保证EV71疫苗研发的顺利进行，中国食品药品检定研究院等相关单位研制了国家抗原定量标准品和标准化的临床样本检测技术，解决了临床样本检测标准化等难题。

Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial  The Lancet, Early Online Publication, 24 January 2013

Background Enterovirus 71 (EV71) outbreaks are a socioeconomic burden, especially in the western Pacific region. Results of phase 1 clinical trials suggest an EV71 vaccine has a clinically acceptable safety profile and immunogenicity. We aimed to assess the best possible dose and formulation, immunogenicity, and safety profile of this EV71 vaccine in healthy Chinese children.

Methods This randomised, double-blind, placebo-controlled, phase 2 trial was undertaken at one site in Donghai County, Jiangsu Province, China. Eligible participants were healthy boys or girls aged 6—36 months. Participants were randomly assigned (1:1:1:1:1) to receive either 160 U, 320 U, or 640 U alum-adjuvant EV71 vaccine, 640 U adjuvant-free EV71 vaccine, or a placebo (containing alum adjuvant only), according to a blocked randomisation list generated by SAS 9.1. Participants and investigators were masked to the assignment. The primary endpoint was anti-EV71 neutralising antibody geometric mean titres (GMTs) at day 56, analysed according to protocol. The study is registered with ClinicalTrials.gov, number NCT01399853.

Findings We randomly assigned 1200 participants, 240 (120 aged 6—11 months [infants] and 120 aged 12—36 months [children]) of whom were assigned to each dose. 1106 participants completed the study and were included in the according-to-protocol analysis. The main reasons for dropout were withdrawal of consent and refusal to donate a blood sample. Infants who received the 640 U adjuvant vaccine had the highest GMTs on day 56 (742·2 [95% CI 577·3—954·3]), followed by those who received the 320 U formulation (497·9 [383·1—647·0]). For children, those who received the 320 U formulation had the highest GMTs on day 56 (1383·2 [1037·3—1844·5]). Participants who received the vaccine had significantly higher GMTs than did who received placebo (p<0·0001). For the subgroup of participants who were seronegative at baseline, both infants and children who received the 640 U adjuvant vaccine had the highest GMTs on day 56 (522·8 [403·9—676·6] in infants and 708·4 [524·1—957·6] in children), followed by those who received the 320 U adjuvant vaccine (358·2 [280·5—457·5] in infants and 498·0 [383·4—646·9] in children). 549 (45·8%) of 1200 participants (95 CI 42·9—48·6%) reported at least one injection-site or systemic adverse reaction, but the incidence of adverse reactions did not differ significantly between groups (p=0·36). The 640 U alum-adjuvant vaccine group had a significantly higher incidence of induration than did the 640 U adjuvant-free group (p=0·001).

Interpretation Taking immunogenicity, safety, and production capacity into account, the 320 U alum-adjuvant formulation of the EV71 vaccine is probably the best possible formulation for phase 3 trials.

Funding The National Science and Technology Major Project (2011ZX10004-902) of the Chinese Ministry of Science and Technology, China's 12—5 National Major Infectious Disease Program (2012ZX10002-001), and Beijing Vigoo Biological.

 

 

中國審批人類精子庫358個

卫生部公布辅助生殖技术开展机构名单 发布时间：2013-3-1 来源：药品资讯网信息中心为主动接受社会监督，引导群众科学就医，2月27日，卫生部向社会公布经批准开展人类辅助生殖技术和设置人类精子库的医疗机构名单。据卫生部妇幼保健与社区卫生司相关负责人介绍，截至2012年12月31日，全国经审批开展人类辅助生殖技术和设置人类精子库的医疗机构共计358个（含由总后勤部卫生部审批的机构）。卫生部将根据人类辅助生殖技术管理专项整治行动及各地审批情况，对该名单进行动态更新。

 

打肺癌疫苗CimaVax EGF 只能去古巴 !

古巴研制出第二种肺癌疫苗 发布时间：2013-3-4 来源：药品资讯网信息中心古巴研制出第二种肺癌疫苗 古巴分子免疫中心研制并注册了一种新的治疗肺癌的疫苗RACOTUMOMAB，这是该中心继CIMAvaxEGF之后研制出的第二种肺癌疫苗，也是该中心2012年最大的科研成果。 古巴分子免疫中心主任阿古斯丁拉赫说，新疫苗RACOTUMOMAB使用方便，在临床试验中显示出"激动人心"的效果，并在欧洲肿瘤内科学会大会上获得广泛认可，其研究论文随后发表于《柳叶刀肿瘤学》杂志上。 拉赫表示，这一新疫苗RACOTUMOMAB今年将开始批量生产，这将使更多的古巴肺癌患者获得及时的干预和治疗，它在海外的注册也已进入日程。 RACOTUMOMAB的研发使古巴继续在世界范围内的肺癌治疗领域保持领先地位。古巴是目前世界上唯一一个研究开发出两种肺癌疫苗的国家。 用于治疗非小细胞肺癌的CIMAvaxEGF疫苗在古巴已进行临床试验，并已获中国国家食品药品管理局的批准在中国医学科学院进行临床试验。 而CIMAvaxEGF肺癌疫苗是世界上唯一注册的此类药品。

Can you tell me about the CimaVax lung cancer vaccine? This page tells you about CimaVax, which is a new vaccine being developed for lung cancer.

What CimaVax is CimaVax EGF is a new vaccine treatment being developed in Cuba for non small cell lung cancer. The vaccine targets a particular protein called epidermal growth factor (EGF). EGF occurs naturally in the body and signals to cells to grow and divide. It does this by attaching to a receptor on the cell surface. Some cancers make the body produce too much EGF so that the cells grow and divide uncontrollably. The CimaVax vaccine is made up of two proteins, one of which is EGF. The vaccine works by stimulating the body's immune response. It encourages the body to make antibodies that recognise and bind to EGF. This stops the EGF attaching to the receptors on cancer cells. So there is no signal telling the cancer cells to grow and divide. This slows the growth of the cancer.

Research into CimaVax The results of a phase 2 trial for people with advanced non small cell lung cancer (NSCLC) were published in early 2008. The trial involved 80 people with stage 3b and stage 4 NSCLC. Everyone in the trial had chemotherapy. After chemotherapy was complete, half of the people had the vaccine. The aims of the trial were to find out

If the vaccine could help people live longer What side effects people have  The immune response people had to it. The results showed that people who had the vaccine lived slightly longer – on average about 4 to 6 months. It also improved people's quality of life by reducing symptoms such as coughing and breathlessness. The trial results also showed that people younger than 60 did better than those who were over 60. There were 12 people under 60 who had a good immune response and their improvement in survival was greatest – they lived on average for just over 15 months compared to 7.4 months for people who didn't have the vaccine. Do remember that this is a small group – 12 is really too small a number to draw any firm conclusions. The side effects of the vaccine were mild. The most common effects were chills, fever and feeling sick. The researchers tested whether people produced antibodies to EGF (an immune response) with a blood test. People who showed an immune response on the test did better than people who did not produce antibodies. This research is promising but this is a small trial and we will need more trial results before we know exactly how well the vaccine works for people with lung cancer. A phase 3 trial is currently in progress in Cuba. There aren't any trials in the UK at the moment.

CimaVax in the UK CimaVax isn't available at the moment in the UK. It has been approved in Cuba and is used in hospitals there. Trials are planned for other countries including America. We need positive results from these trials before CimaVax can become more widely available.

 

罗氏临床研究rochetrials.com

罗氏为药物临床试验数据建新渠道 发布时间：2013-3-4 来源：药品资讯网信息中心罗氏近日宣布，正在扩大第三方研究人员查询该公司临床试验数据的渠道。罗氏将与经认证的专家组成的独立团体一起评价和批准查询患者原始资料的请求。罗氏支持旗下所有获批药物的全部临床研究报告(CSRs)由监管当局发布，根据研究人员的请求提供监管当局所不能提供的临床研究报告。"本着满足患者与制药企业最佳利益的原则，我们理解和支持要求制药企业临床试验数据透明化的诉求，"罗氏首席营运官Daniel O'Day说。"同时，我们坚持认为卫生监管机构需要对药物的评价与批准把好关。我们认为，已经找到了一条将患者数据提供给第三方研究人员的途径，但该途径必须处于能够确保患者信息保密并避免发布误导性的结果。 罗氏继续提供药品监管机构要求的所有信息，临床试验结果同时由rochetrials.com和clinicaltrials.gov两个网站以摘要的形式提供。罗氏同时也将在适当时候向欧盟的EudraCT数据库提交数据。

 

 

生技漲幅過大! 要提出說明???

嚴查風聲鶴唳 主力落跑！ 興櫃生技股摔得鼻青臉腫 2013年3月4日 16:55【鉅亨網記者張旭宏 台北】 主管機關要介入調查！台股生技股倒一片，使得興櫃生技股主力大量撤出，拖累股價持續重挫，4日跌幅前10大都是生技股，包含康富(4140-TW)、久裕(4173-TW)、安成(4180-TW)、賽德(4156-TW)、國鼎(4132-TW)、泉盛(4159-TW)、永昕(4726-TW)、慕德生(4740-TW)、因華(4172-TW)跌幅超過10%；另外中裕(4147-TW)、彥臣(4732-TW)、友霖(4166-TW)也有8%以上跌幅；寶齡(1760-TW)有5%以上跌幅。由於興櫃市場沒有漲跌幅限制，加上生技股從去年第四季在政府政策做多帶動下，新藥生技開始飆漲，因此今年開始主力即鎖定生技股，幾天漲幅倍增，快速炒股，大賺興櫃財，因此上周聽聞主管單位要介入調查時，主力紛紛撤出，因此使得興櫃生技股跌的鼻青臉腫！ 根據統計，今年以來興櫃漲幅逾1倍的公司高達10檔，幾乎都是生技類股，其中生技股的寶齡居冠，漲幅逾3倍，另外永昕、安成藥、浩鼎、因華、中裕等漲幅也有8以上。券商表示，興櫃新藥股近期漲得實在太誇張，確實需要降溫了！此時主管機關介入，可以讓興櫃市場恢復正常的機制，避免流於本夢比的高風險，最後受傷還是投資大眾！ 券商承銷商高層指出，確實收到重申今年興櫃新制的事件，並要求漲幅過大的個股，要主辦證券商按法規辦理並提出說明，同時設法遏止興櫃生技股不當炒作歪風，對於股價異常的公司，個別電話通知客戶，提醒客戶留意投資風險。

拼也要拼下去? 等待奇蹟誰說的算!

兩難！無效醫療一年一千七百億 2013-03-04中廣新聞 陳奕華 基於孝心、不捨，面對親人臨終，家屬總希望還能拼到起死回生的機會，患者卻承受不小折磨。統計顯示，國內一年花在無效醫療上約一千七百億，今天十九個醫療團體大串連，呼籲民眾簽署安寧緩和意願書，讓自己活的快樂、病得健康、死的尊嚴。父母先後因為心肌梗塞去世，從積極持續搶救父親，到順從母親意願讓她離開，台灣醫療品質促進聯盟秘書長曾中龍感慨的說：「或許我的母親是因為當時我父親的狀況，當時讓她有覺悟，所以她不想造成孩子痛苦，當時我父親（急救）92天，醫療支出好龐大，當時也沒有健保只有勞保，可能有這樣心理準備，所以她根本不想要回來，我哭是因為我母親到最後，都可以考量到，我們家決定讓她走吧。」前衛生署長楊志良曾說，健保每年五千多億，一千六、七百億以上用來送終，指的就是無效醫療。台灣醫療品質促進聯盟理事長連瑞猛指出，很多家屬堅持拼到最後，不僅死者痛苦，離開的狀態也讓家屬很難接受，呼籲經醫師判定不可逆，與其積極治療，不如積極安寧，串連包括台灣麻醉護理學會等十九個團體，推廣拒絕無效醫療觀念，欲立安寧緩和醫療意願書，讓患者病的健康、走的尊嚴。

 

松山湖四大支柱 (台湾高科技园、两岸生技合作基地、大学创新城、中以国际产业园)

以超常规手段支持松山湖超常规发展 2013-02-27 09:19:20来源: 东莞日报 郑家雄 摄 东莞市委副书记、市长袁宝成昨日轻车简从，一路实地调研台湾高科技园、两岸生物技术产业合作基地规划建设情况，并听取了松山湖管委会发展情况汇报。在与松山湖管委会负责同志座谈时，袁宝成说，去年，松山湖各项指标发展高于全市水平，但解放思想尚有空间，开拓创新尚存潜力，支持方式仍可创新。经过十年的开发，松山湖的发展进入"厚积薄发"期，接下来要力争实现超常规发展。希望松山湖进一步解放思想、开拓创新、以超常规的手段和超常规的支持力度取得超常规的发展。 副市长张科陪同调研。调研时，市政府就松山湖具体的发展问题进行协调解决。

四个平台今年建设要取得明显进展 座谈时，袁宝成听取了市政府副秘书长、松山湖管委会工委书记刘宁关于松山湖发展情况的汇报。"未来5年，松山湖计划营业收入年均增长至少20％。"刘宁说，大学创新城、台湾高科技园、两岸生物技术合作基地、中以国际科技产业园四个市重大平台是松山湖建设"增长极"的重要依托，这四个平台建设今年要取得明显进展。 在谈及台湾高科技园建设时，刘宁说，到2017年台湾高科技园力争实现营业总收入600亿元以上，总税收36亿元以上。其中，今年计划启动投资额20亿元的一批载体和配套项目建设。截至去年年底，台湾高科技园已累计投资约25亿元，协议引资额达110亿元，包括联胜科技项目及一批IC和生物医药企业。

两岸生物医药 计划五年内投入95亿元搭建平台 目前，"两岸生物技术合作基地"已引进了多个从事生物技术研发的高校和研究机构，去年实现工业总产值2.13亿元。未来五年，该基地计划投入95亿元搭建公共技术服务平台体系，力争到2017年实现营业性收入300亿元。

发展阶段 松山湖的发展进入"厚积薄发"期 在充分肯定松山湖过去一年的工作成绩后，袁宝成说，今后的松山湖要站在对城市未来发展负责任的高度，主动寻找差距。"经过十年的开发，松山湖的发展进入'厚积薄发'期"。接下来，松山湖管委会要进一步解放思想，开拓创新，以超常规的手段和超常规的支持力度取得超常规的发展。 对松山湖的发展，袁宝成提出四点要求，要求松山湖尽快实现科技、产业、人才超常规的发展： 一要抓好领导班子和队伍建设。积极打造出一支纪律严明、战斗力强、能干事业的队伍；二要完善好松山湖发展机制。如果没有好的工作机制，就没有超常规发展的保障；三要全力推动重大平台建设。今年省委全会报告19次提到东莞工作，充分说明东莞很多工作得到了省里认可，上升到了全省高度，松山湖台湾高科技园、中以产业园和两岸生物技术合作基地等项目写入省委报告，大家要有紧迫感，加大工作力度，实现超常规发展；四要加大政策支持力度。市政府各部门要进一步加大支持松山湖的力度，充分放权，授够权限，让松山湖有充分的发展自主权。通过超常规的支持，使松山湖有超常规的办事效率。同样，松山湖各项工程建设必须保证质量和廉洁。（实习编辑 邹长森）

 

TNT佈局全球臨床檢體 運送 TSR一級認證 !!

荷商TNT天遞「亞洲陸運網絡」獲高科技資產保護協會（TAPA）頒布「貨運安全（TSR）」項目一級認證。另為迎春及回饋客戶，TNT昨宣布即日起自至四月十九日止，凡使用TNTExpress任何台灣付費之進、出口服務至日本、新加坡、韓國及泰國，且運費達新台幣一萬元，即可兌換TNT飛機造型行李吊牌一個。

台灣分公司總經理李澂涓昨表示，TNT近年積極佈局急速發展的亞洲市場，並擁有綿密的航空運輸網絡與快速安全的運送銜接服務，目前亞洲陸運網絡已超過七千六百五十公里，橫跨一百二十七個亞洲城市，TNT看到市場對完整供應鏈安全性的強大需求，進一步打造各項高安全標準運送流程規範，這次榮獲TAPA認證為中國與東南亞間最完整「戶對戶運輸網」之業者，包含曼谷、香港及新加坡等地，並擁有整合性區域道路、航空樞紐、運務中心與倉儲的認可。李澂涓表示，TNT元月進、出口雙成長，進口額更創新高，搭上企業景氣回溫趨勢，TNT特別推出獨家滿額禮活動吸客，活動期間之簽約顧客，不限進、出口服務至指定亞洲國家（日本、新加坡、韓國及泰國），滿萬元即贈「TNT獨家飛機造型行李吊牌乙個」，且同帳號使用不同限定國家之進、出口服務，皆可合併累積金額，僅需在四月三十日前至活動網站線上申請即可獲得，數量有限，請把握時間。

Clinical Express Our Clinical Express service is a unique service for the medical, pharmaceutical and biotech industries. We deliver time and temperature-sensitive clinical samples and supplies for laboratories and clinical establishments, quickly and safely.

This special handling service covers all clinical movements including specimen supplies and medication/ specialist packaging and dry ice supply service/ door-to-door collection and delivery for patients, doctors and investigators/ full tracking of your shipments provides complete visibility/ consultancy on import/export customs clearance . We also provide specialist transportation for medicines and medical equipment.

Single partner TNT PharmaSafe provides you with a single partner, as we control the full end-to-end supply chain: from providing pre-conditioned packaging, handling shipments in our own stations, using our own aircraft and pick-up and delivery network for transport, and providing robust customs processes using in-house staff. Real time tracking of location and temperature

TNT PharmaSafe  provides real time tracking of location and temperature during transport. The temperature both inside and outside the container is constantly measured – also during flights. This data is fed real time to TNT's 24/7 PharmaSafe Control Tower using a GSM transponder that is only switched off during flights (like mobile phones).  TNT PharmaSafe provides cost effective multi modal solutions. We run a fleet of 46 own aircraft that cover 71 airports in 30 countries in Europe and connect between Europe, Asia, Middle East and the US and we operate a fleet of 30,000 road vehicles and more than 2,600 depots and sorting centers worldwide.

微創顱內覆膜支架

微創醫療(00853.HK)新產品獲准在內地銷售推廣 2013-02-28 08:57:19阿思達克財經新聞 微創醫療(00853.HK)公布，集團產品Willis顱內覆膜支架系統獲國家食品藥品監督管理局批准於國內銷售及推廣。 集團將儘快實施與此產品相關的銷售及營計劃。Willis顱內覆膜支架系統主要用於治療顱內動脈瘤。

鑫品 減資發行新股(2013)

鑫品生醫：鑫品生醫科技股份有限公司一○一年度減資暨現金增資股票發放日公告 鉅亨網新聞中心2013-03-05 17:09:19 壹、本公司101年減少實收資本額新臺幣92,139,980元，銷除已發行股份9,213,998股之減資案，及現金增資新臺幣140,000,000元，共計14,000,000股，每股新臺幣10元整之增資案，業經台北市政府102年2月4日府產業商字第10281043700號函核准變更登記在案。茲訂於102年03月21日（星期四）起以集保帳簿劃撥無實體方式交付。貳、茲將本次減資暨現增發行新股有關事項公告如下： 一、原已發行股票：記名式普通股18,427,996股，每股面額10元整，計新臺幣 184,279,960元整。二、減資發行新股：記名式普通股9,213,998股，每股面額10元整，計新臺幣92,139,980元整。三、現增發行新股：記名式普通股14,000,000股，每股面額10元整，計新臺幣140,000,000元整。四、實收資本額：記名式普通股23,213,998股，每股面額10元整，計新臺幣232,139,980元整。五、新股之權利義務與原發行之股份相同。六、股票證簽證機構：以集保帳簿劃撥無實體方式交付。參、本次新股訂於102年03月21日（星期四）起開始發放，茲將發放方式說明如下：請 憑本公司寄發之「一○二年減資及現增股票發放暨全面無實體換發通知書」，填妥相關資料，並提供集保存摺封面影本，蓋妥原留印鑑逕向（或掛號郵寄）台北市中正區重慶南路一段10號11樓（電話：（02）23826789）本公司股務代理人「日盛證券股份有限公司股務代理部」辦理。（辦理時間：週一至週五上午8：30至12：00，下午1：30至4：00）俟相關申請檔案審核無誤後，即可將新股劃撥至股東之集保帳戶。肆、除分函各股東外，特此公告。

 

北榮啟用新複合手術室 醫療更安全

時間：2013/2/23 新聞引據： 中央社台北榮總醫療團隊23日正式啟用最新複合式手術室，結合高階影像檢查與手術在同一時間內完成，縮短手術時間、提高成功率與安全性。 台北榮總今天(23日)正式啟用最新複合式手術室，結合高階影像檢查與手術在同一時間內完成，縮短手術時間、提高成功率與安全性。台北榮民總醫院院長林芳郁表示，一個成功的手術，除需要醫療團隊的精湛技術外，還需要高科技手術室設備，「最新複合式手術室」將改變國內手術方式，提供病患最安全的手術環境。北榮外科部心臟血管外科主任施俊哲表示，最新複合式手術室去年3月動工，12月底完工並開始使用，至今已執行約50例病例；為達超低落塵手術室要求，所有標準都比其他手術室嚴格，並運用最新數位心血管攝影X光機，快速取像顯示重組後的3D結果，並在6秒鐘內完成360度旋轉攝影。施俊哲說，在傳統手術室施行血管腔內手術時，需反覆以人工方式推進X光機提供透視影像，耗時又耗人力，影像清晰度也有限，若有必要以高解析度X光機檢查，則需再將病人送到手術室以外的檢查室檢查。他說，最新複合式手術室可提供不同手術使用，如大動脈血管支架置入、微創主動脈瓣膜置換等手術，結合影像與手術，減少病患手術時間，同時也可減少患者麻醉劑、顯影劑劑量及輻射量。施俊哲說，高階的攝影檢查可減少因心臟跳動或病人呼吸而造成的假影，提供更準確影像，提高手術精準與成功率，另外也可從不同地點透過網路連線到手術室，啟動同步雙向視訊教學與即時影像傳輸。

 

成功大學醫療器材創新聯盟

台灣/成大醫療器材創新聯盟交流座談連結學界與產業界 2013-03-04 18:27:06蔡清欽/報導成功大學頂尖計畫投注的「成功大學醫療器材創新聯盟」，已經號召71個會員，是台灣的生技醫療產業最有活力的聯盟，為了聯結學術研究和產業界，醫療器材創新聯盟不斷舉辦論壇，以及交流座談會，以倍增醫療器材的研究能量。「成功大學醫療器材創新聯盟」交流座談會三月四日下在成大自強校區召開，由計畫總主持人為賴明詔院士，共同總主持人有蘇芳慶教授共同主持，成大副校長顏鴻森和研發總中心主任蔡明祺，與聯盟會員30多家創新醫療器材廠商，來自產學研醫約八十人與會，分別由學界蘇芳慶主任、郭榮富副教授提出主題交流，並由SportsSportsArt郭海濱董事長與鴻君科技呂坤衡副總經理提出會員經驗交流。賴明詔院士表示，成大醫療器材創新聯盟整合成大醫學院、醫院與工程學院之教授及臨床醫師團隊發展高階醫療器材，在六大新興產業的主題與架構上建立一個平臺，以推進臺灣剛起飛的醫療器材產業，過去一年多以來的努力，大家有目共睹，所有的研究努力都是為了增進人類的健康與福祉。蘇芳慶教授則以「創新醫材產業的趨勢與機會」為題，展開經驗分享，他說「2012年行政院生技產業策略諮議委員會議」(BTC)明示台灣發展生技產業，應該加強聚焦品項市場端與基礎應用研究端的銜接，早日建構以市場導向的研究與銜接機制，可藉由「產業出題」創造產學、建教合作的行動方案，吸引產業界第三棒直接「引進上游案源」，進一步強化生技產業策略與環境。 【中央網路報】

 

 

詹宏志：兩岸電子商務不對等

詹宏志：網路是關鍵策略產業 2013-02-25 01:13 工商時報 【記者何英煒／專訪】PChome Online網路家庭集團董事長詹宏志去年底接下台灣網路暨電子商務產業發展協會（TIEA）理事長一職，身為網路產業的大家長，他對政府提出鄭重的呼籲「應將網路產業視為關鍵性的策略產業」，如此一來，不但為產業升級找到一條路，台灣所有的產業都會變強，更可以解決台灣年輕人世代失落的困境！

問：您認為台灣網路產業目前現況如何？答：我認為還不壞，但心中仍相當擔憂，因為台灣網路產業在吃老本。在2000年之前，台灣的網路產業發展得還不錯。一方面政府有明確的政策，例如，喊出三年三百萬人上網等具體目標。另外，台灣多所大學早年有聯合網路，加上資訊產業快速發展也培育出一批能力很強的工程師。像是台灣的104網站、PChome Online，一開始的架構就可容納大型流量，大陸直到近年才跟上；而台灣的電子商務型態涵蓋B2C、C2C及開店平台等，相當多元豐富。

政府沒有明確政策

問：您提到的擔憂是指？答：我認為台灣的網路產業發展其實是後繼無力！我稱之為「失落的十五年」。在過去15年內，社會上對於這個產業沒有看法，政府也沒有明確政策，民間對於網路產業沒有投資的勇氣。

問：身為TIEA的理事長，可否談一談今年具體的目標？答：希望政府可以明確的表示，標舉出網路產業是政府要推動的關鍵性策略產業。只要這個政策出來，每個部會都會去檢討現有的計畫和法令並進行整合。

問：政府也的確提出了幾個政策，如華文電子商務及三業四化等，也相當重視網路產業呀？答：可惜沒有明確、單獨的標舉「網路產業」這四個字。這也使得許多政策分散在不同的目標及計畫中，以不同型態呈現出來，可能是文創、可能是電信服務。就因為沒有一個上位的政策概念，當有議題與現有架構衝突時，解釋出來的東西可能是A也可能是B。如果有一個總體產業的重要宣示，當現在的工作方式與過去規範不同時，政府部門就會積極的來解決它。如果政府明確宣示要發展網路產業，現在散在各部會、七零八落、與網路相關的計畫就會集中起來，力量也會不一樣。而三業四化（即製造業服務化、服務業科技化、服務業國際化、傳統產業特色化），中小企業要如何國際化？製造業要如何服務化？關鍵就是「網路化」，但最重要的這句話為何沒有說出來呢？

兩岸電子商務不對等

問：業者究竟遇到那些困難，可以談談嗎？答：以華文電子商務來說，現在的重心放在「華文」及「商務」，既然是華文，一定要包含中國大陸，既然要做商務，買東西、賣東西就算，但最後的結果是把賣東西的商家送到大陸的網路平台。這個計畫如果沒有發展「網路」，華文電子商務根本就是假的。中國大陸淘寶網在台灣開課，政府補貼業者去上課，淘寶網來台灣招商，政府官員去站台，這不都亂了嗎？兩岸電子商務根本沒有對等，任何網路公司都需要取得ICP執照才能進入大陸，但這個ICP執照取得難度跟媒體一樣。連中國大陸網民上台灣主要網路公司的網站也不行，因為都被封鎖起來。兩岸既然有ECFA的談判，電子商務第一天就被列為其中，政府談判時應該要正視這個議題。

問：法令無法與時俱進，讓業者吃足了苦頭?答：就拿台北市政府與Google Play應用程式商店的衝突為例，過去電子商務一直以郵購的相關法令來看待，業者只好接受七天鑑賞期的規範，但當下載型的軟體及數位內容商品出現時，這就出現了問題。以歐盟為例，針對數位內容也有鑑賞期，例如給消費者15分鐘的試用時間。

法令落後需要正視 當台北市政府與Google起了衝突，Google收費的APPS（應用程式）暫不上架，這對使用者、開發商、平台業者及官方，每一方都是傷害。這個官司一來一往就是一年多，台灣禁得起嗎？然而，我們沒有看到政府官員對此表示態度，就代表沒有什麼人知道事情的嚴重性。真正嚴重的地方在此!!1998年時，網路家庭與台新銀行共同成立了Payeasy這家公司，當時就是想要做支付，如果那時可以做的話，將是比Paypal、Alipay（支付寶）都來得早，實際狀況是，到現在還沒有辦法做。15年過去了，從創新角度，我們沒有任何落後，反而有領先。法令落後是不足為奇，但對於這樣的事情，政府應該要有回應，產業領袖也要有看法。

問：您提到發展網路產業可解決年輕人世代失落的困境？答：過去台灣的力量都是放在製造業上，而其特質就是控制成本，過去台灣選擇了這樣的發展目標，如果沒有升級，那麼22K工資就是「種瓜得瓜」的結果。可是如果政府及產業意識到「網路產業很重要」，實體零售部門說我要複製一個網路事業部、服務業要產生網路服務部門，製造業說，我要透過網路來擴大接單和服務。做品牌的說，要通過網路來直接接觸消費者。如此一來，所有的產業通通都會變得強大。而這個過程中，所需要聘雇的員工都是年輕人。如果政府宣示要發展網路產業，全部年輕人的就業機會就會活起來。

 

宣明智….把台灣生技能量放大!!!

不搶兒子光彩 宣明智快閃 2013-03-02 02:02 工商時報 【杜蕙蓉】即使曾經吵了3年，宣明智昨（1）日在兒子宣昶有的場子，只陪同工研院院長蔡清彥至會議室門口，拋了一句「和工研院的合作，是要聯手把台灣的生技能量放大」就火速走人，深怕搶了兒子的光彩，也怕話題失焦。宣昶有說，他擁有醫學及商學背景，曾是執業的中醫針灸師及內科醫師，並擁有幹細胞培養技術專利，從事中西醫及生物科技研究近十年，始終無法忘情生醫產業。他認為新世紀一定是中國文化的天下，而中醫思維將是另類的醫療趨勢，不管是新藥或醫材都融入中醫的概念。不過，生技的投資風險長，與IT產業的快速發展有很大的分歧，宣明智父子就常為此爭論，宣明智認為，生技產品成熟須要7-8年，以電子業7-8月就有產品上市，就要經歷一場汰舊換新大賽，生技產品風險太高。但宣昶有認為，以有競爭性產品來看，聯發科的晶片、宏達電的智慧型手機研發到產品上市，也是要花上7-8年時間，其實兩者的競爭和風險是一樣的！宣昶有不諱言，很多人都會說，家世背景不錯，何必出來低頭對外募資。不過，他看到的是，現在已是個生技的時代，IT產業的人也很想投資，只是看不懂而已！對宣昶有來說，由於有個有名的富爸爸，對商譽和投資更顯得重要，前幾年，他在大陸投入毛囊幹細胞研究，後來覺得要等到商品化路程實在太遙遠了，因此，他把儲存的毛囊幹細胞金額全數退給當事人。投資萊特失利，他也是快刀斬亂麻，在在都說明他揹負的責任和成功壓力更甚於一切。據了解，為了贊助宣昶有的生技大夢，宣明智不僅找來交大幫的科技大老共襄盛舉投資， 也為了怕兒子亂燒錢，宣捷生技也由聯電集團佔了一點股份，並佔了董監事席次，就近監督，宣明智護子之情不言而喻。

 

 

郑州台湾科技园投资说明会

郑州台湾科技园日前举办深港企业投资说明会 华夏经纬网 2013-01-23 09:43:35 近日，郑州台湾科技园首次正式"发声"深圳特区，在深圳五洲宾馆举办了"郑州新郑综合保税区（航空港区）?郑州台湾科技园深港企业投资说明会"，与来自深圳投资商会的30多家知名企业代表，进行了全方位沟通，并与数十家深圳知名企业达成了投资意向。在深港企业联谊会上，郑州新郑综合保税区（航空港区）管委会主任张延明致辞，与深圳市政协副主席周长瑚、中兴集团董事长侯为贵等企业界、政界人士进行深入交流，并详细介绍了郑州台湾科技园的建设情况及发展前景，一句"今日的郑州航空港，就是明日的深圳"，更是赢得现场阵阵掌声。据悉，张延明主任一行辗转深圳、广州、中山、珠海四市参观考察了广药集团陈李济制药有限公司、白云山和记黄埔制药有限公司、广州宝莱特等生物医药科技企业，受到了当地商界的广泛关注，当地企业均对郑州台湾科技园区承接产业转移的区位优势及政策优势表示极大的兴趣。（郑州市台办） 责任编辑：李欣

 

 

朱敬一歐盟演說介紹台醫療科技

 23:02:25 （中央社記者曹宇帆布魯塞爾5日專電）中華民國行政院國家科學委員會主任委員朱敬一今天在歐洲議會發表演說，介紹台灣遠距科技長期照護服務及新藥研發成就，令聆聽演說的國際專家學者與主管官員印象深刻。朱敬一此行是應歐洲聯盟邀請，出席歐盟科學論壇並發表演說；今天舉行演說的場地正是歐洲議會外交委員會經常使用的會議廳。歐盟科學論壇（EU Science）由歐盟理事會輪值主席國愛爾蘭主辦，邀請加拿大等國衛生醫療與科技部會官員，以及各領域科技專家學者百餘人與會，朱敬一是唯一受邀來自亞洲國家的部長級官員。歐洲各國十分重視人口結構高齡化的全球趨勢，朱敬一在演說中介紹台灣使用視訊科技提供妥善的遠距長期照護服務，凸顯台灣資訊科技的進步。朱敬一提到台灣對華人常見疾病例如肝癌等新藥研發，與中國大陸合作進行臨床試驗的方式，讓與會者瞭解台灣與中國大陸合作研製新藥的作法，可增進人類福祉。在為時約20分鐘的演說結束後，朱敬一與來自各國產官學界代表廣泛交換意見，場面熱絡。1020305